Matches in Wikidata for { <http://www.wikidata.org/entity/Q64658193> ?p ?o ?g. }
Showing items 1 to 34 of
34
with 100 items per page.
- Q64658193 description "clinical trial" @default.
- Q64658193 description "ensayu clínicu" @default.
- Q64658193 description "klinisch onderzoek" @default.
- Q64658193 description "клінічне випробування" @default.
- Q64658193 name "Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease" @default.
- Q64658193 type Item @default.
- Q64658193 label "Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease" @default.
- Q64658193 prefLabel "Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease" @default.
- Q64658193 P1050 Q64658193-6C666903-48AC-409C-88FA-EF42351EAEC8 @default.
- Q64658193 P1132 Q64658193-AA561715-77CF-4615-82D6-C8D876954595 @default.
- Q64658193 P1476 Q64658193-9FD19735-6461-4322-90DB-5B2227752E49 @default.
- Q64658193 P17 Q64658193-1AE5D486-579D-4D6C-8B59-125559BBAF58 @default.
- Q64658193 P2899 Q64658193-42F806BD-A7E7-4D98-869C-A8F026C7AA89 @default.
- Q64658193 P3098 Q64658193-3DE1D8DD-CAEE-423D-94BF-94F754455324 @default.
- Q64658193 P31 Q64658193-E55121DD-7F11-489C-80E6-F70D51AD4F78 @default.
- Q64658193 P580 Q64658193-96C21F28-637D-48F5-BFC5-9A9A70862D5C @default.
- Q64658193 P582 Q64658193-B134CBEC-E157-4F6F-BF74-39BDF2BAA42E @default.
- Q64658193 P6099 Q64658193-DEEC61C3-1691-4944-BD88-4938DBC4CE25 @default.
- Q64658193 P8363 Q64658193-E0705689-574C-454A-A5FB-993132CED0D9 @default.
- Q64658193 P921 Q64658193-17351CEE-1986-4F74-B5B9-A59FCD36911E @default.
- Q64658193 P921 Q64658193-ECF56905-8C37-4F81-A21E-49EBE01B0669 @default.
- Q64658193 P1050 Q12206 @default.
- Q64658193 P1132 "+129" @default.
- Q64658193 P1476 "A Multi-Center, Open-Label, Randomized, Parallel Group, Dose-Ranging, Pharmacodynamic Phase II Trial to Determine the Effects of Bardoxolone Methyl (RTA 402, Amorphous Dispersion) on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease (eGFR 15-45 mL/Min/1.73m2)" @default.
- Q64658193 P17 Q30 @default.
- Q64658193 P2899 "+18" @default.
- Q64658193 P3098 "NCT01053936" @default.
- Q64658193 P31 Q30612 @default.
- Q64658193 P580 "2010-01-01T00:00:00Z" @default.
- Q64658193 P582 "2010-12-01T00:00:00Z" @default.
- Q64658193 P6099 Q42824440 @default.
- Q64658193 P8363 Q78089383 @default.
- Q64658193 P921 Q1129105 @default.
- Q64658193 P921 Q19001011 @default.